Novartis to buy Takeda eye drug assets in US$3.4bil deal


HONG KONG: Novartis AG has agreed to pay US$3.4bil for eye-disease medicines that Takeda Pharmaceutical Co is selling to shed debt after its US$62bil acquisition of Shire Plc.

The main product in the deal is Xiidra, prescription drops that compete with Allergan Plc’s blockbuster Restasis to relieve dry-eye disease, a common condition that can hinder daily activities ranging from reading to driving. Along with US$3.4bil in cash upfront, Novartis agreed to pay as much as US$1.9bil in milestones.

Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!
   

Next In Business News

Malaysia maintaining 4-5% GDP growth forecast for 2023 - Ahmad Maslan
Asian stocks slide to lowest this year on rate worries
Vital to support SMEs to tap supply chains shifting to Asean - Tengku Zafrul
Malaysia rises to 18th place in Global Financial Inclusion Index
Australia c.bank pauses rates for 4th month as Bullock's debut signals continuity
Finance industry must cooperate to combat financial crime, scams - AICB
Boustead Plantations, KLK securities trading halt
Reservoir Link subsidiary proposes listing on Nasdaq
Evergrande shares volatile as trade resumes amid chairman probe
FBM KLCI rises slightly amid cautious environment

Air Pollutant Index

Highest API Readings

    Select State and Location to view the latest API reading

    Source: Department of Environment, Malaysia

    Others Also Read